174 related articles for article (PubMed ID: 23528596)
1. [Additional indicators of the assessment of efficacy of disease modifying drugs (preliminary results)].
Iakushina TI; Lizhdvoĭ VIu; Vasilenko IA; Andriukhina OM; Kotov SV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):61-5. PubMed ID: 23528596
[TBL] [Abstract][Full Text] [Related]
2. [Disease modifying drugs in multiple sclerosis and pregnancy].
Tur C; Tintoré M; Aguilera C
Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
[No Abstract] [Full Text] [Related]
3. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
Johnston J; So TY
Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
[TBL] [Abstract][Full Text] [Related]
4. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
[TBL] [Abstract][Full Text] [Related]
5. [Update on current care guidelines: multiple sclerosis].
Duodecim; 2013; 129(5):548-9. PubMed ID: 23520898
[TBL] [Abstract][Full Text] [Related]
6. Multiple sclerosis: Switching sides--fingolimod versus injectable MS therapies.
Rossman IT; Cohen JA
Nat Rev Neurol; 2015 Jun; 11(6):316-7. PubMed ID: 25896088
[No Abstract] [Full Text] [Related]
7. [Multiple sclerosis and pregnancy].
Ruuskanen J; Malm H; Airas L
Duodecim; 2013; 129(14):1457-64. PubMed ID: 23961604
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom.
Agius M; Meng X; Chin P; Grinspan A; Hashmonay R
CNS Neurosci Ther; 2014 May; 20(5):446-51. PubMed ID: 24684973
[TBL] [Abstract][Full Text] [Related]
9. Treatment decisions for patients with active multiple sclerosis.
Stüve O; Centonze D
JAMA Neurol; 2015 Apr; 72(4):387-9. PubMed ID: 25664937
[No Abstract] [Full Text] [Related]
10. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Sørensen PS
J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
[TBL] [Abstract][Full Text] [Related]
11. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
12. [Multiple sclerosis: current therapies and future perspectives].
Matsushita T
Nihon Rinsho; 2011 Nov; 69(11):2077-86. PubMed ID: 22111333
[TBL] [Abstract][Full Text] [Related]
13. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
Komoly S
Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178
[No Abstract] [Full Text] [Related]
14. Editorial: the pitfalls of combination therapy.
Vermersch P
Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
[No Abstract] [Full Text] [Related]
15. [Current treatment of multiple sclerosis].
Csépány T
Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
17. New drugs may improve, complicate treatment for multiple sclerosis.
Link H; Martin R
Nat Med; 2010 Mar; 16(3):272. PubMed ID: 20208513
[No Abstract] [Full Text] [Related]
18. New management algorithms in multiple sclerosis.
Sorensen PS
Curr Opin Neurol; 2014 Jun; 27(3):246-59. PubMed ID: 24759080
[TBL] [Abstract][Full Text] [Related]
19. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.
Freedman MS
Eur J Neurol; 2014 Mar; 21(3):377-87, e18-20. PubMed ID: 24237582
[TBL] [Abstract][Full Text] [Related]
20. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
